Methods of treating dry eye disease using TNF alpha antagonists
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
Nov 19, 2024
Grant Date -
Jun 13, 2019
app pub date -
Jun 19, 2017
filing date -
Jun 19, 2017
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNFα antagonist, e.g., a TNFα antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNFα antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNFα antagonist, e.g., a TNFα antibody, such as LME636.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully